Neosoma Receives Renewed SOC2 Type II Certification

Neosoma, a leading provider of medical technology solutions to advance the treatment of brain tumors, announced today that it has received, for a third year, SOC 2 Type II compliance, in accordance with American Institute of Certified Public Accountants (AICPA) standards for SOC for Service Organizations, also known as SSAE 18.

Safeguarding customer and patient data is paramount to Neosoma’s mission, and the SOC 2 independent review process serves as third-party industry validation that Neosoma provides enterprise-level security and management of customer data secured in the company’s systems.  Receiving an unqualified opinion on a SOC 2 Type II audit report is a significant achievement and demonstrates Neosoma’s commitment and adherence to the highest data security standards.

Michael Hill, Neosoma’s Chief Technology Officer, said, “Since Neosoma received its first SOC 2 Type II attestation in 2023, we have worked to maintain and expand upon our procedures and processes to safeguard our customer data.  This third attestation reflects Neosoma’s commitment to security, provides transparency into our processes, and allows our customers to feel confident that their patient information stays safe while we provide them with Neosoma’s unique analytical disease insights.”

The Neosoma mission is to support brain tumor clinical care and clinical trials, by building a portfolio of AI-based software modules that provide clinicians with greater insights to help guide treatment techniques and clinical management decisions, as well as support clinical trials for the development of new treatment options in the hope to one day find a cure.